News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Arbios Systems (ABOS) Acquires Assets From Circe Biomedical, Inc.

10/19/2005 5:10:59 PM

LOS ANGELES--(BUSINESS WIRE)--April 21, 2004--Arbios Systems, Inc. (BB: ABOS), a biomedical device company with proprietary liver assist technologies useful in the diagnosis and treatment of acute liver failure, announced today that it has acquired certain assets of Circe Biomedical, Inc. ("Circe"). The acquired assets include, among others, Circe's intellectual property portfolio, rights to a bioartificial liver ("BAL") (HepatAssist)(TM) and related technologies, clinical and marketing data, a Phase III IND, and over 400 manufacturing and QA/QC standard operation protocols previously reviewed by the Food and Drug Administration. The assets were acquired in exchange for a $200,000 upfront payment and a $250,000 deferred payment due the earlier of April 12, 2006 or when the Company has raised accumulated gross proceeds of $4 million from the issuance of debt or equity securities.

Circe's HepatAssist(TM) is based on a BAL technology platform that was developed by the founders of Arbios, Drs. A. A. Demetriou and J. Rozga. The technology was licensed from Cedars-Sinai Medical Center in Los Angeles, CA, to W.R. Grace & Co. in 1994 who then eventually transferred the technology to Circe Biomedical, Inc.

HepatAssist(TM) is an extracorporeal (outside the body) liver failure therapy device, in which the function of porcine liver cells is supplemented by a detoxification column filled with charcoal particles. Arbios' LIVERAID(TM) is being developed to provide more liver support than the HepatAssist by combining much larger number of liver cells and expanded blood detoxification in a proprietary cartridge with unique fiber-in-fiber geometry.

HepatAssist was tested by Circe in 171 liver failure patients in a Phase II/III prospective, randomized, controlled trial in 11 U.S. and 9 European medical centers. This trial did not achieve its primary endpoint (30-day survival) in the overall study population. However, when adjusting for the impact of liver transplantation on patient survival, patients with fulminant and subfulminant hepatic failure treated with the HepatAssist had a statistically significant survival advantage compared to controls receiving standard medical care. HepatAssist also demonstrated a favorable safety profile. The outcome of the study becomes more important when taking into account the heterogeneity of the patient population, the large number of centers involved with varying local standards of care and the high degree of severity of illness of the study population (an article summarizing the results of Circe's clinical trials will appear in the upcoming issue of the Annals of Surgery).

"We are pleased to acquire the proprietary technology, know-how and wealth of data collected by Circe during the development of HepatAssist," commented Dr. Jacek Rozga, Arbios' CEO. "We view the HepatAssist system as our first generation bioartifical liver and we are glad that this promising technology returned 'home.' With HepatAssist, Circe demonstrated for the first time that extracorporeal cell based therapy is a safe and viable therapy in liver failure patients. With the knowledge gained through the work on HepatAssist, we hope to expedite the development of LIVERAID(TM) and revolutionize the way liver failure patients are treated thereby increasing their chances of survival."

At present no direct treatment for liver failure is available and patients must receive a liver transplant or endure prolonged hospitalization with a significant mortality rate. However, only a small percentage of liver failure patients receive a transplant due to shortage of donor livers. Further, many patients cannot be transplanted because of alcohol or drug abuse, infection, cancer, cardiovascular disease, etc. There is, therefore, an urgent need for artificial means of liver assistance to facilitate recovery from liver failure without a transplant.

Arbios Systems, Inc. is an early-stage biomedical device company engaged in the discovery, acquisition and development of proprietary liver assist devices and new technologies useful in the diagnosis and treatment of acute liver failure, a debilitating and fatal disease. Arbios' two lead products are SEPET(TM), a novel blood purification therapy employing selective plasma filtration, and LIVERAID(TM), a second-generation BAL.

This press release contains forward-looking statement, that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the assets acquired from Circe Biomedical, Inc. and ability of Arbios to complete the development of LIVERAID(TM), the need for subsequent substantial additional financing to complete clinical development of Arbios' products, and Arbios' ability to successfully market its products and technologies. These statements represent the judgment of Arbios' management as of this date and are subject to risks and uncertainties that could materially affect the company. The company does not undertake any obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SEPET and LIVERAID are trademarks of Arbios Technologies, Inc., the subsidiary of Arbios Systems, Inc.


Arbios Systems, Inc. Amy Factor, 973-377-7665 or

Wolfe Axelrod Weinberger Associates LLC Donald C. Weinberger, 212-370-4500

Read at

Related News

comments powered by Disqus